United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $548.96, for a total value of $5,215,120.00. Following the sale, the chief executive officer owned 40,513 shares in the company, valued at $22,240,016.48. The trade was a 19.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Trading Up 3.0%

Shares of UTHR opened at $563.70 on Wednesday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The firm has a market cap of $23.93 billion, a price-to-earnings ratio of 20.81, a PEG ratio of 1.80 and a beta of 0.58. The stock has a 50 day moving average of $557.76 and a 200-day moving average of $528.73.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period in the prior year, the company posted $6.63 earnings per share. The business’s revenue was down 1.6% on a year-over-year basis. On average, sell-side analysts predict that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Large investors have recently modified their holdings of the company. Geneos Wealth Management Inc. grew its position in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in shares of United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 70 shares during the last quarter. Jump Financial LLC acquired a new position in shares of United Therapeutics during the second quarter worth approximately $277,000. Cerity Partners LLC boosted its position in shares of United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after buying an additional 5,600 shares during the period. Finally, Bank of Nova Scotia grew its holdings in United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock worth $468,000 after buying an additional 105 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent research reports. Raymond James Financial started coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. HC Wainwright boosted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday, May 7th. Finally, TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.